SLNO SLNO R2K
Company Profile ↓Company Overview
SLNO (SLNO) is a publicly traded company listed on with a market capitalization of $2.77B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.12.
Generates positive free cash flow, funding growth and shareholder returns internally.
Growth & Price Performance
Stock Price Performance
| 1 Year: | - |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 135.9.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 32.66M | 66.02M | 91.73M | 94.60M |
| Cost of Revenue | - | - | 0 | 696.00K | 1.14M | 863.00K | 1.20M |
| Gross Profit | - | - | 0 | 31.96M | 64.88M | 90.87M | 93.41M |
| Operating Expenses | - | - | 42.78M | 37.38M | 42.16M | 50.44M | 61.64M |
| Operating Income | - | - | -42.78M | -5.42M | 22.72M | 40.43M | 31.76M |
| EBITDA | - | - | -41.91M | -2.83M | 27.91M | 45.22M | 36.72M |
| Interest Expense | - | - | 1.36M | 1.38M | 1.39M | 1.35M | 1.29M |
| Pretax Income | - | - | -43.77M | -4.71M | 26.01M | 43.36M | 34.91M |
| Tax Provision | - | - | - | - | - | - | 3.54M |
| Net Income | - | - | -43.77M | -4.71M | 26.01M | 43.36M | 31.38M |
| Diluted EPS | - | - | -0.95 | -0.09 | 0.47 | 0.80 | 0.59 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 190.41M |
| Cost of Revenue | - | - | 0 | 0 | 2.70M |
| Gross Profit | - | - | 0 | 0 | 187.71M |
| Operating Expenses | - | 25.11M | 38.67M | 184.43M | 172.75M |
| Operating Income | - | -25.11M | -38.67M | -184.43M | 14.95M |
| EBITDA | - | -22.10M | -37.03M | -173.63M | 28.38M |
| Interest Expense | - | 0 | 0 | 231.00K | 5.48M |
| Pretax Income | - | -24.07M | -38.99M | -175.85M | 20.89M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -24.07M | -38.99M | -175.85M | 20.89M |
| Diluted EPS | - | -2.87 | -2.36 | -4.38 | 0.39 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 26.50M | 180.69M | 330.97M | 563.83M |
| Current Assets | - | 15.65M | 171.36M | 293.89M | 355.81M |
| Cash & Equivalents | - | 14.60M | 169.68M | 87.93M | 70.11M |
| Inventory | - | - | - | 0 | 15.02M |
| Receivables | - | - | - | 0 | 28.21M |
| Total Liabilities | - | 16.15M | 23.18M | 85.86M | 113.72M |
| Current Liabilities | - | 7.31M | 11.51M | 18.75M | 61.36M |
| Long Term Debt | - | - | - | 49.83M | 49.86M |
| Total Debt | - | 155.00K | 403.00K | 52.83M | 52.55M |
| Total Equity | - | 10.35M | 157.51M | 245.11M | 450.12M |
| Shares Outstanding | - | 8.16M | 31.68M | 45.70M | 52.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -20.78M | -24.94M | -69.10M | 46.80M |
| Investing Cash Flow | - | -13.00K | 0 | -225.68M | -201.78M |
| Financing Cash Flow | - | 14.09M | 180.02M | 213.03M | 137.16M |
| Capital Expenditure | -22.00K | -13.00K | - | -218.00K | -73.00K |
| Free Cash Flow | - | -20.79M | -24.94M | -69.31M | 46.73M |
| Net Change in Cash | - | -6.70M | 155.08M | -81.75M | -17.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 98.6% |
| Operating Margin % | - | - | - | - | 7.9% |
| Net Margin % | - | - | - | - | 11.0% |
| ROE % | - | -232.6% | -24.8% | -71.7% | 4.6% |
| ROCE % | - | -130.9% | -22.9% | -59.1% | 3.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SLNO
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Navigating A Stable Path In Biotechnology - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNUVJrZXNIaUloTjNJaFZWUjZfbkdBMHFYMXNPWVRTQU92VzJNTklHQWJuZktJaVgtNnhET01SYWpQRXdqejJDQzBDWk5YUDU0cU91SDFmeUVNU0N1b2JKbGxsWGlXTVU3THppQlFOWW9ja1dHQUdpOVpSR1FybzYyUWlIS2szVDZKMTJBb2…
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPTExjSGFEZGRPOHlNRWE5aEcxZ01VUjZIa083bFlzTnNFVXp6U3haeFZsaXR0Q3hpa2lYajJSR09iUFhRa3p3WjJ4SExyRmhfNlduaWlvYy1CN2pFSW1ER2c4dUs4dGhCS1UwUWkwUThzTTJLMjJ4enpjMVFhQ3N2TWtRNV9ZYTZ3dzlVbS…
Soleno Therapeutics Stock Skyrockets 33% After Neurocrine Biosciences Announces Acquisition Deal - TIKR.com
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNR3prUzJSb2FmYm9LUDVBbElERnJkV0ZhZ1k5S0dkTURzYVBaT0dYWWhWZjlwRDk2ek5fdkl5bGdMaUFrOWRPdEVnQWpZd2l1TGZLcWxUV01ObzRLdUQwUENQQkQyLWdoTVRDWVYzaWVaYUU3ZkwtVGp0WUlNakkwYlRha1p6NkVleTY3Z1…
Soleno Therapeutics (SLNO) Soars 32% on $2.9-Billion Merger - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPRktKNzdBdmIyVFNtdTFvZjZoWkd0WE1XWEdfXzZ6M0FpUjF0dFRBeEktcllvbXdjZmkwZEVvbEdOVWFxS1l3UzhfUDdBNXFWQVVDbjNIamViQldxNnNkbzJCVW5WckwtNkg2QktKRjhJeHdBb0NWQVdkVDBmSDV1WmtRNGRmUFRPcVpMdV…
Soleno Therapeutics jumps on $2.9B all-cash buyout deal at $53/share | SLNO Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNRDZXZzZJT3FaZUdTdjVuVXQ0WHVHeGV0UTFoX0QyTHI3SVJwcHpzanB3b1otVlpCVnZkWWpvV29YaXJqWms3Z3lTWVpjQ2VkcWxQTTJCZlcwcVRqcW8wdHZ4MlZuSERDcTdjeXYxQWd5RXBmRHRMaDRKb1h6TFZpS0tjeUZ2dDZmRGNQNl…
SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action - PR Newswire
<a href="https://news.google.com/rss/articles/CBMinAJBVV95cUxOOU9fTjFlWEVxSUpFLXU4TnBRVnFHSm1IclJHRWR5TXVCUXZzMmpKQkVuUDQ0ZDJZUEhxUGZTYnI1Mmw0MENCVzRoNzhxeEFWUkExMzZhN0NoWkUzb3N5QzIyQmx2NWREdHBQZXpmZjVwYVBYTlEwdXpBeG1UYVpGZFl5NzZ2aER6di1fVW…
SLNO — Frequently Asked Questions
What is the current share price of SLNO?
As of 2026-07-14 21:23 PDT, SLNO trades at $53.01 on NASDAQ/NYSE. Its 52-week range is $53.01 to $53.01.
What is the market capitalisation of SLNO?
SLNO has a market capitalisation of $2.77B on NASDAQ/NYSE.
What is the P/E ratio of SLNO?
SLNO trades at a trailing price-to-earnings (P/E) ratio of 135.92. Its price-to-book (P/B) ratio is 6.16.
What is the return on equity (ROE) of SLNO?
SLNO has a return on equity (ROE) of 4.64%. Its return on capital employed (ROCE) is 2.98%.
Is SLNO a good stock to buy?
This page provides a data-driven analysis of SLNO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.